These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 30626765)

  • 1. Associations Between Multiple Circulating Biomarkers and the Presence of Atrial Fibrillation in Hypertrophic Cardiomyopathy with or Without Left Ventricular Outflow Tract Obstruction.
    Liu L; Wu L; Zheng L; Ding L; Chen G; Fan X; Yao Y
    Int Heart J; 2019 Mar; 60(2):327-335. PubMed ID: 30626765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between P wave dispersion, atrial electromechanical delay, left atrial remodeling, and NT-proBNP levels, in patients with hypertrophic cardiomyopathy.
    Tuluce K; Ozerkan F; Yakar Tuluce S; Yavuzgil O; Gurgun C; Bilgin M; Kahya Eren N; Kocabas U; Nalbantgil S; Soydas Cinar C
    Cardiol J; 2015; 22(1):94-100. PubMed ID: 24671901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Okawa M; Yamanaka S; Hirota T; Hoshikawa E; Hayato K; Yamasaki N; Matsumura Y; Yasuda N; Sugiura T; Doi YL
    Clin Cardiol; 2010 Feb; 33(2):E1-7. PubMed ID: 20043329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy.
    Tesic M; Seferovic J; Trifunovic D; Djordjevic-Dikic A; Giga V; Jovanovic I; Petrovic O; Marinkovic J; Stankovic S; Stepanovic J; Ristic A; Petrovic M; Mujovic N; Vujisic-Tesic B; Beleslin B; Vukcevic V; Stankovic G; Seferovic P
    J Cardiol; 2017 Oct; 70(4):323-328. PubMed ID: 28336204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study.
    Li X; Chen C; Gan F; Wang Y; Ding L; Hua W
    BMC Cardiovasc Disord; 2014 May; 14():67. PubMed ID: 24885051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation.
    Tian H; Cui J; Yang C; Hu F; Yuan J; Liu S; Yang W; Jiang X; Qiao S
    BMC Cardiovasc Disord; 2018 Nov; 18(1):207. PubMed ID: 30390664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy: clinical characteristics and risk factors].
    Wu X; Cui H; Wang JJ; Xiao MH; Lu J; Zheng XX; Guo Y; Wang SY; Huang XH
    Zhonghua Nei Ke Za Zhi; 2017 Mar; 56(3):184-187. PubMed ID: 28253598
    [No Abstract]   [Full Text] [Related]  

  • 8. Alteration of serum biomarkers in patients with hypertrophic cardiomyopathy with and without atrial fibrillation.
    Sari M; Yazar H; Kocayigit I; Karagoz A; Ayturk M; Fidan S; Arslantas U; Cakmak EO; Alici G; Ozkan B
    Biomark Med; 2021 Sep; 15(13):1131-1142. PubMed ID: 34402630
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictors of Future Atrial Fibrillation Development in Patients with Hypertrophic Cardiomyopathy: A Prospective Follow-Up Study.
    Tuluce K; Yakar Tuluce S; Kahya Eren N; Kocabas U; Akyildiz Akcay F; Gunduz R; Akyildiz ZI; Ergene O
    Echocardiography; 2016 Mar; 33(3):379-85. PubMed ID: 26493159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction.
    Letsas KP; Filippatos GS; Pappas LK; Mihas CC; Markou V; Alexanian IP; Efremidis M; Sideris A; Maisel AS; Kardaras F
    Clin Res Cardiol; 2009 Feb; 98(2):101-6. PubMed ID: 18975023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.
    Park JR; Choi JO; Han HJ; Chang SA; Park SJ; Lee SC; Choe YH; Park SW; Oh JK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):763-72. PubMed ID: 21516440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
    Thaman R; Esteban MT; Barnes S; Gimeno JR; Mist B; Murphy R; Collinson PO; McKenna WJ; Elliott PM
    Am J Cardiol; 2006 Aug; 98(4):515-9. PubMed ID: 16893708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.
    Arteaga E; Araujo AQ; Buck P; Ianni BM; Rabello R; Mady C
    Am Heart J; 2005 Dec; 150(6):1228-32. PubMed ID: 16338263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation.
    Bai M; Yang J; Li Y
    Clin Cardiol; 2009 Dec; 32(12):E1-5. PubMed ID: 20014208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Okawa M; Yamanaka S; Hirota T; Baba Y; Hayato K; Yamasaki N; Matsumura Y; Yasuda N; Sugiura T; Doi YL
    Circ J; 2011; 75(4):919-26. PubMed ID: 21304210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes.
    Büttner P; Schumacher K; Dinov B; Zeynalova S; Sommer P; Bollmann A; Husser D; Hindricks G; Kornej J
    Heart Rhythm; 2018 Aug; 15(8):1132-1137. PubMed ID: 29604419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy.
    Liu L; Liu S; Shen L; Tu B; Hu Z; Hu F; Zheng L; Ding L; Fan X; Yao Y
    Clin Cardiol; 2020 Oct; 43(10):1150-1159. PubMed ID: 32810305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of NT-proBNP for New-onset Atrial Fibrillation in the Acute Phase of Myocardial Infarction.
    Dong Z; Hou X; Guo C
    Altern Ther Health Med; 2024 Oct; 30(10):528-532. PubMed ID: 38401102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.